CD52 and hemophagocytic syndrome: Additional treatment modalities include immunoglobulins, anti-thymocyte globulin (ATG), interleukin-1 antagonist (anakinra) and monoclonal antibodies against CD52 (alemtuzumab), interleukin-6 (tocilizumab), TNF-α (infliximab) and CD20 (rituximab, in EBV triggered HLH) [2, 3, 8].